Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa

Recruiting

Phase 2

Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis SuppurativaTrial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa

Sponsor:

Phoenicis Therapeutics

Code:

NCT05020730

Conditions

Hidradenitis Suppurativa

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PTM-001

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-02. This information was provided to ClinicalTrials.gov by Phoenicis Therapeutics on 2022-10-26.